Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells

Oncogene volume 25, pages 6113–6122 (2006)Cite this article

Abstract

A major obstacle for clinicians in the treatment of advanced prostate cancer is the inevitable progression to chemoresistance, especially to docetaxel. It is essential to understand the molecular events that lead to docetaxel resistance in order to identify means to prevent or interfere with chemoresistance. In initial attempts to detect these events, we analysed genomic differences between non-resistant and docetaxel-resistant prostate tumor cells and, of the genes modulated by docetaxel treatment, we observed Stat1 and clusterin gene expression heightened in the resistant phenotype. In this study, we provide biochemical and biological evidence that these two gene products are related. Stat1 and clusterin protein expression was induced upon docetaxel treatment of DU145 cells and highly overexpressed in the docetaxel-resistant DU145 cells (DU145-DR). The increase in total Stat1 corresponded to an increase in phosphorylated Stat1. Interestingly, there was no detectable difference between DU145 and DU145-DR cells expression of total Stat3 and phosphorylated Stat3. Treatment of DU145-DR cells with small interfering RNA targeted for Stat1 not only resulted in the knockdown of Stat1 expression, but it also caused the inhibition of clusterin expression. Thus, Stat1 appears to play a key role in the regulation of clusterin. Remarkably, inhibition of Stat1 or clusterin expression resulted in the re-sensitization of DU145-DR cells to docetaxel. These results offer the first evidence that Stat1, and its subsequent regulation of clusterin, are essential for docetaxel resistance in prostate cancer. Targeting this pathway could be a potential therapeutic means for intervention of docetaxel resistance.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Assikis VJ, Do KA, Wen S, Wang X, Cho-Vega JH, Brisbay S et al. (2004). Clin Cancer Res 10: 6770–6778.

  • Barton BE, Murphy TF, Shu P, Huang HF, Meyenhofer M, Barton A . (2004). Mol Cancer Ther 3: 1183–1191.

  • Bettuzzi S, Davalli P, Astancolle S, Carani C, Madeo B, Tampieri A et al. (2000). Cancer Res 60: 28–34.

  • Cochet O, Frelin C, Peyron JF, Imbert V . (2006). Cell Signal 18: 449–455.

  • Culine S, Droz JP . (2000). Ann Oncol 11: 1523–1530.

  • Darnell Jr JE . (1997). Science 277: 1630–1635.

  • Debatin KM, Poncet D, Kroemer G . (2002). Oncogene 21: 8786–8803.

  • De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI et al. (2004). J Cell Biochem 91: 459–477.

  • DeMiguel F, Lee SO, Lou W, Xiao X, Pflug BR, Nelson JB et al. (2002). Prostate 52: 123–129.

  • Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC . (2002). Prostate 51: 241–246.

  • El-Hashemite N, Zhang H, Walker V, Hoffmeister KM, Kwiatkowski DJ . (2004). Cancer Res 64: 3436–3443.

  • Geney R, Ungureanu M, Ojima I . (2002). Clin Chem Lab Med 40: 918–925.

  • Hengartner MO . (2000). Nature 407: 770–776.

  • Herr I, Debatin KM . (2001). Blood 98: 2603–2614.

  • Ho SM, Leav I, Ghatak S, Merk F, Jagannathan VS, Mallery K . (1998). Am J Pathol 153: 131–139.

  • Horvath CM . (2000). Trends Biochem Sci 25: 496–502.

  • Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR . (1999). J Biol Chem 274: 6875–6881.

  • Johnstone RW, Ruefli AA, Lowe SW . (2002). Cell 108: 153–164.

  • July LV, Beraldi E, So A, Fazli L, Evans K, English JC et al. (2004). Mol Cancer Ther 3: 223–232.

  • Lacroix H, Ligeza C . (1998). Expert Opin Investig Drugs 7: 273–281.

  • Lee SO, Lou W, Johnson CS, Trump DL, Gao AC . (2004). Prostate 60: 178–186.

  • Legrand A, Vadrot N, Lardeux B, Bringuier AF, Guillot R, Feldmann G . (2004). Liver Int 24: 149–160.

  • Liu K, Caldwell SA, Abrams SI . (2005). Cancer Res 65: 1045–1054.

  • Lowe SW, Lin AW . (2000). Carcinogenesis 21: 485–495.

  • Kominsky SL, Hobeika AC, Lake FA, Torres BA, Johnson HM . (2000). Cancer Res 60: 3904–3908.

  • Makarovskiy AN, Siryaporn E, Hixson DC, Akerley W . (2002). Cell Mol Life Sci 59: 1198–1211.

  • Milbank AJ, Dreicer R, Klein EA . (2002). Urology 60: 738–741.

  • Miller ML, Ojima I . (2001). Chem Rec 1: 195–211.

  • Miyake H, Chi KN, Gleave ME . (2000a). Clin Cancer Res 6: 1655–1663.

  • Miyake H, Hara I, Kamidono S, Gleave ME, Eto H . (2003). Oncol Rep 10: 469–473.

  • Miyake H, Nelson C, Rennie PS, Gleave ME . (2000b). Cancer Res 60: 170–176.

  • Miyake H, Pollak M, Gleave ME . (2000c). Cancer Res 60: 3058–3064.

  • Nelson WG, De Marzo AM, Isaacs WB . (2003). N Engl J Med 349: 366–381.

  • Nickerson T, Miyake H, Gleave ME, Pollak M . (1999). Cancer Res 59: 3392–3395.

  • O'Sullivan J, Whyte L, Drake J, Tenniswood M . (2003). Cell Death Differ 10: 914–927.

  • Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC . (2001). Carcinogenesis 22: 965–973.

  • Peto J . (2001). Nature 411: 390–395.

  • Petrylak DP . (2005). Urology 65: 3–7.

  • Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. (2004). N Engl J Med 351: 1513–1520.

  • Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG . (2004). Oncogene 23: 2298–2304.

  • Stephanou A, Latchman DS . (2003). Int J Exp Pathol 84: 239–244.

  • Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. (2004). N Engl J Med 351: 1502–1512.

  • Thomas M, Finnegan CE, Rogers KM, Purcell JW, Trimble A, Johnston PG et al. (2004). Cancer Res 64: 8357–8364.

  • Trougakos IP, Gonos ES . (2002). Int J Biochem Cell Biol 34: 1430–1448.

  • Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES . (2004). Cancer Res 64: 1834–1842.

  • Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S et al. (2004). Nat Med 10: 48–54.

  • Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K et al. (2003). BJU Int 92: 463–469.

  • Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP et al. (2001). J Pharmacol Exp Ther 298: 934–940.

Download references

Acknowledgements

This work was supported by NIH Grants AI056213 and CA98080, and by Aventis Pharmaceuticals. We thank Linda Mora for her technical support on immunohistochemistry. We would also like to thank the Molecular Imaging Core and the Flow Cytometry Core at H Lee Moffitt Cancer Center.

Author information

Author notes

  1. S G Patterson and S Wei: These two authors contributed equally to the work and are first authors.

Authors and Affiliations

  1. Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, FL, USA

    S G Patterson, S Wei, X Chen, D A Sallman, D L Gilvary, B Zhong, J Pow-Sang, T Yeatman & J Y Djeu

  2. Genitourinary Oncology Program, Tampa, FL, USA

    S G Patterson & J Pow-Sang

  3. Immunology Program, H Lee Moffitt Cancer Center, Tampa, FL, USA

    S Wei, X Chen, D A Sallman, D L Gilvary, B Zhong & J Y Djeu

Authors
  1. S G Patterson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D A Sallman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D L Gilvary
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Pow-Sang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Yeatman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Y Djeu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Y Djeu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patterson, S., Wei, S., Chen, X. et al. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 25, 6113–6122 (2006). https://doi.org/10.1038/sj.onc.1209632

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209632

Keywords

This article is cited by

Search

Advanced search

Quick links